BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Other Marketed & Partnered Products by Year
Other Marketed & Partnered Products — Net Product Revenue ($M) ($M)
BeOne Medicines Other Marketed & Partnered Products: $83.7M in FY2025, down 12.9% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Segment Disaggregation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Marketed & Partnered Products — Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.7 | -12.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 96.1 | -19.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 119 | +225.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 36.7 | +376.6% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 7.70 | +3,750.0% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0.20 | – | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up other Marketed & Partnered Products
- PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY20–FY23)6.70 · FY2023
- REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24)36 · FY2024
- VIDAZA (azacitidine — BMS/Celgene China Partnered) ($M, FY18–FY23)14 · FY2023
- ABRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21)0 · FY2021
Cite this data
StockData. (2026). BeOne Medicines Other Marketed & Partnered Products ($M), annual FY2018–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-other-tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.